Page 3 - Hematologic Malignancies News Today

Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.

Guenther Koehne, MD, PhD, discusses research efforts to overcome resistance to CAR T-cell therapy in hematologic malignancies.

Early treatment administration with this regimen also promoted a faster decrease in viral load and shorter viral shedding in patients with hematologic diseases who were positive for COVID-19.

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing...

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executiv...

Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging The Gaps in Hematologic Malignancies meeting.

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.